Hepatitis C: Epidemiology, Transmission, and Screening. Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Hepatitis C: Epidemiology, Transmission, and Screening. Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco"

Transcription

1 Activity Code FA376

2 Hepatitis C: Epidemiology, Transmission, and Screening Jennifer Price, MD Assistant Professor of Medicine University of California San Francisco

3 Learning Objectives Upon completion of this presentation, learners should be better able to: Recognize trends in the epidemiology of HCV infection Successfully implement HCV screening guidelines

4 Faculty and Planning Committee Disclosures Please consult your program book. There will be no off-label/investigational uses discussed in this presentation.

5 Causes of Death Among HIV+ 40% 35% 30% 25% 20% 15% 10% 5% 0% AIDS Liver Cardiac Cancer Other Causes of death in 33,308 HIV+ adults followed prospectively in the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study. Adapted from D:A:D Study Group.AIDS 2010, 24:

6 Chronic HCV Epidemiology Worldwide: ~3% (170 million) chronically infected Global prevalence varies depending on area Up to 20% in highly endemic areas such as Nile Delta 5 million are HIV-HCV coinfected United States: % ( million) chronically infected with HCV 8% are HIV-infected 25-30% of HIV+ in US are also HCV+: prevalence varies by transmission risk factor WHO: CDC: Lavanchy D. Clin Microbiol Infect. 2011;17: Ghany, et al. Hepatology.2009;49:

7 Global Prevalence of HCV 2.9% % % <1.0% No data

8 Global Prevalence of HCV 1>2,3 1>2>3 1>3>2 2>1 4 3>1,2 1>2>6 2.9% % % <1.0% No data 5 1>3,6>2 1>2,3

9 Which of the following is the most efficient mode of HCV transmission? A. Heterosexual contact B. Injection drug use C. Maternal-child transmission D. Male homosexual contact 25% 25% 25% 25% A. B. C. D. 8

10 Transmission of HCV Mother-child transmission 2-5%; 5 x higher if mother is HIV+ CDC: Yeong et al.. Hepatology. 2001;34(2):223. Mast et al.. J Infect Dis. 2005;192:

11 Anti-HCV+, % Prevalence of HIV-HCV by HIV Risk Factor Injection Drug Use Heterosexual Contact Sulkowski and Thomas. Ann Intern Med. 2003;138: Male Homosexual Contact Entire Cohort

12 HCV Transmission: Serodiscordant heterosexual couples N Incidence (per year) Piazza Italy (1997) 499 1% Kao Taiwan (2000) % Vandelli Italy (2004) 776 0% Tahan Turkey (2005) 216 0% Terrault United States (2013) % Piazza et al Arch Intern Med 1997; 157: ; Kao et al J Gastroenterol Hepatol 2000;15: ; Vandelli et al. Am J Gastroenterol 2004;99: ; Tahan et al. Am J Gastroenterol 2005;100: ; Terrault et al. Hepatology 2013;57:

13 Browne et al. Sex Transm Infect 2004; 80: Gilleece et al. J Acquir Immune Defic Syndr 2005; 40: Gambotti, et al. Euro Surveill 2005; 10: Ghosn, et al. HIV Med 2004; 5: Gotz et al. AIDS 2005; 19: Luetkemeyer et al. J Acquir Immune Defic Syndr 2006; 41: Fierer, et al. J Infect Dis 2008; 198: HCV Transmission: HIV+ MSM 2004/2005: Clusters of acute HCV in HIV+ MSM reported in Northern Europe Ulcerative STI s more common in HCV incident cases Molecular genetics more similar to each other than to IDU-associated HCV isolates Linkages made to high-risk sexual behavior (fisting, group sex, traumatic and receptive intercourse) and recreational (not-injected) drugs

14 Browne et al. Sex Transm Infect 2004; 80: Gilleece et al. J Acquir Immune Defic Syndr 2005; 40: Gambotti, et al. Euro Surveill 2005; 10: Ghosn, et al. HIV Med 2004; 5: Gotz et al. AIDS 2005; 19: Luetkemeyer et al. J Acquir Immune Defic Syndr 2006; 41: Fierer, et al. J Infect Dis 2008; 198: HCV Transmission: HIV+ MSM Clusters of acute HCV among HIV+ MSM reported in both US and Australia Northern Europe cohort studies suggests increased HCV incidence since 2000 Short time frame (<2 years) between HIV diagnosis and HCV seroconversion

15 Hepatitis C History 1973: Non-A non-b viral hepatitis described HBV discovered 1965 HAV blood testing developed : HCV genome cloned 1989: HCV antibody test commercially available in US 1990: HCV PCR test developed

16 Estimated Incidence of Acute HCV in US, Surrogate testing of blood donors Decline among transfusion recipients Anti-HCV test (1 st generation) licensed Anti-HCV test (2 nd generation) licensed Decline among injection drug users Source: CDC

17 Incidence of Acute HCV in US, , by Age Group Source: National Notifiable Diseases Surveillance System (NNDSS)

18 HIV impacts which of the following among HCV-infected individuals? A. Clearance of acute HCV infection B. Progression to cirrhosis C. Survival after development of cirrhosis D. Graft and patient survival after liver transplant E. All of the above 20% 20% 20% 20% 20% A. B. C. D. E. 8

19 Natural History of HCV Acute HCV Resolved 15-40% Chronic HCV 60-85% Stable 85-90% Cirrhosis 10-15% Slowly progressive 75% HCC Liver failure 25% (2-4%) NIH Management of Hepatitis C Consensus Conference Statement. June 10-12, 2002.

20 Complications of Cirrhosis Ascites Variceal bleed Hepatic encephalopathy Grade I: Changes in behavior, mild confusion, disoriented sleep Grade II: Lethargy, moderate confusion Grade III: Stupor, incoherent speech Grade IV: Coma, unresponsive to pain Hepatocellular carcinoma

21 Natural History of HIV/HCV Lower rates of spontaneous clearance Resolved 15-40% Acute HCV Chronic HCV 60-85% Stable 85-90% Cirrhosis 10-15% Slowly progressive 75% HCC Liver failure 25% (2-4%) NIH Management of Hepatitis C Consensus Conference Statement. June 10-12, 2002.

22 Natural History of HIV/HCV Acute HCV Resolved 15-40% Chronic HCV 60-85% Accelerated fibrosis progression Stable 85-90% Cirrhosis 10-15% Slowly progressive 75% HCC Liver failure 25% (2-4%) NIH Management of Hepatitis C Consensus Conference Statement. June 10-12, 2002.

23 Natural History of HIV/HCV Acute HCV Resolved 15-40% Chronic HCV 60-85% Stable 85-90% Cirrhosis 10-15% Increased risk of decompensation Slowly progressive 75% HCC Liver failure 25% (2-4%) NIH Management of Hepatitis C Consensus Conference Statement. June 10-12, 2002.

24 Natural History of HIV/HCV Acute HCV Resolved 15-40% Chronic HCV 60-85% Stable 85-90% Cirrhosis 10-15% Slowly progressive 75% HCC Liver failure 25% (2-4%) Liver Transplant Death Shorter survival after decompensation

25 Natural History of HIV/HCV Acute HCV Resolved 15-40% Chronic HCV 60-85% Stable 85-90% Cirrhosis 10-15% Slowly progressive 75% HCC Liver failure 25% (2-4%) Liver Transplant Poorer outcomes after liver transplant Death

26 Burden of Chronic HCV in the US 193,000 HCV deaths next 10 yrs 1.83 million person-years of life lost $11 billion in direct medical care costs $21.3 and $54 billion societal costs from premature disability & mortality million 1.1 million 800, million Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press; 2010; Wong Am J Pub Health 2000

27 Annual Age-Adjusted Death Rate Due to HCV is Higher than HIV 0.21 per 100, per 100, per 100, Underlying/contributing cause Total Deaths Age-adjusted/100,000 HCV 15, ( HIV 12, ( ) HBV 1, ( ) Ly et al. Ann Intern Med 2012;156:271-8

28 Which of the following is a true statement regarding HCV screening? A. Over 50% of individuals with chronic HCV in the US are undiagnosed B. All pregnant women should be screened for HCV C. Screening is not recommended for patients who only used injection drugs once D. All patients meeting HCV screening criteria should undergo HCV nucleic acid testing 25% 25% 25% 25% A. B. C. D. 8

29 The Problem of Undiagnosed Infection million 45-85% undiagnosed 1.1 million 21% undiagnosed 800, million 65% undiagnosed Institute of Medicine. Hepatitis and Liver Cancer: A National Strategy for Prevention and Control of Hepatitis B and C. Washington, DC: The National Academies Press; 2010.

30 Risk-based Screening Unsuccessful Among high-risk populations for whom routine HCV testing is recommended, prevalence of testing = 17-87% Why? Limited access to care, patients uncomfortable with disclosing risk behaviors, poor recall of remote events Time constraints on physicians, reluctance to ask questions about risky behaviors, lack of knowledge Smith B, et al. MMWR. 2012; 61(RR04);1-18.

31 CDC Releases Birth Cohort Screening Guidelines Adults born during should receive one-time testing for HCV without prior ascertainment of HCV risk All persons identified with HCV infection should receive a brief alcohol screening and intervention as clinically indicated, followed by referral to appropriate care and treatment services Smith BD, et al. MMWR Recomm Rep. 2012;61(RR-4):1-32.

32 Prevalence of HCV By Year of Birth NHANES Data, and Anti-HCV prevalence among persons born during : 3.25% 5 x higher than among adults born in other years Armstrong GL, et al. Ann Internal Med. 2006;144: Smith BD, et al. AASLD 2011.

33 US Birth Cohort With HCV Generating the Greatest Demand for LT Biggins SW, et al. Liver Transpl. 2012;18:

34 HCV Screening Guidelines Anyone born between 1945 and 1965 HIV-infected History of illicit injection drug use or intranasal cocaine use, even if only used once Received clotting factors made before 1987 Ever on chronic hemodialysis Persistently elevated ALT level Informed that they received blood from a donor who later tested positive for HCV Received blood/organs before July 1992 Children born to HCV-infected mothers. Needle stick injury or mucosal exposure to HCV+ blood Smith, et al. MMWR Recomm Rep 2012; 61:1-32.

35 Projected Health Impact of Birth Cohort Recommendations Outcome Birth Cohort Testing With Therapy PR PR + DAA Additional cases identified 808, ,580 Cirrhosis cases averted 138, ,000 Decomp. cirrhosis cases averted 50,000 74,000 HCC cases averted 32,000 47,000 Liver transplants averted 11,000 15,000 Deaths from HCV averted 82, ,000 Medical costs averted $1.5 billion $2.5 billion Cost/QALY gained $15,700 $35,700 DAA, direct-acting antiviral; PR, peginterferon/ribavirin Rein DB, et al. Ann Intern Med. 2012;156:

36 HCV Screening Among HIV+ All patients should be screened for HCV at least once Annual HCV testing recommended for*: Injection drug users HIV+ men who have unprotected sex with men *European AIDS Clinical Society recommends annual HCV screening in all HIV+ persons IDSA Primary Care Guidelines for Management of Persons Infected with HIV: 2013 Update AASLD/IDSA Recommendations for Testing, Managing, and Treating Hepatitis C: 2014

37 anti-hcv antibody HCV Screening If positive HCV RNA confirmatory testing HCV RNA testing anti-hcv positive anti-hcv negative but suspect acute HCV anti-hcv negative but severely immunocompromised

38 HCV Linkage to Care Falck-Ytter, et al. Ann Intern Med. 2002;136: Grebely, et al J Viral Hepat. 2009;16: Mehta SH, et al. AIDS. 2006;20: Mehta SH, et al. J Community Health. 2008;33: Hallinan, et al. Drug Alcohol Depend. 2007;88:49-53.

39 Key Points HCV Epidemiology and Screening HCV incidence peaked in US in 1980 s Long-term sequelae occur decades after infection Majority of chronically infected are undiagnosed One-time screening recommended for all baby boomers and all HIV+ Challenges Implementation of screening recommendations Identifying those with advanced fibrosis/cirrhosis Linkage to care

40 Activity Code FA376

Hepatitis C Epidemiology: 2015 Update

Hepatitis C Epidemiology: 2015 Update Hepatitis C Epidemiology: 2015 Update Vincent Lo Re, MD, MSCE Assistant Professor of Medicine and Epidemiology Division of Infectious Diseases Center for Clinical Epidemiology and Biostatistics University

More information

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965

Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 Recommendations for the Identification of Chronic Hepatitis C virus infection Among Persons Born During 1945-1965 MMWR August 17, 2012 Prepared by : The National Viral Hepatitis Technical Assistance Center

More information

Using Electronic Medical Record Decision Support to Increase Testing for Hepatitis C

Using Electronic Medical Record Decision Support to Increase Testing for Hepatitis C Using Electronic Medical Record Decision Support to Increase Testing for Hepatitis C Camilla S. Graham, MD, MPH Division of Infectious Diseases Beth Israel Deaconess Medical Center None Disclosures Advantages

More information

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis

HEPATITIS WEB STUDY Acute Hepatitis C Virus Infection: Epidemiology, Clinical Features, and Diagnosis HEPATITIS WEB STUDY Acute C Virus Infection: Epidemiology, Clinical Features, and Diagnosis H. Nina Kim, MD Assistant Professor of Medicine Division of Infectious Diseases University of Washington School

More information

A medical provider guide: Screening for hepatitis C infection in people living with HIV

A medical provider guide: Screening for hepatitis C infection in people living with HIV Living well with hepatitis C and HIV education series A medical provider guide: Screening for hepatitis C infection in people living with HIV Have you diagnosed every case of hepatitis C? Between 1 in

More information

The ABCs of Hepatitis A, B and C Serology Tests: Common Uses in Primary Care. Dr Aaron Woo Consultant Div of Gastroenterology, Dept of Medicine

The ABCs of Hepatitis A, B and C Serology Tests: Common Uses in Primary Care. Dr Aaron Woo Consultant Div of Gastroenterology, Dept of Medicine The ABCs of Hepatitis A, B and C Serology Tests: Common Uses in Primary Care Dr Aaron Woo Consultant Div of Gastroenterology, Dept of Medicine Outline: Clinical Question Approach Clinical Questions, The

More information

Preface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636)

Preface. TTY: (888) 232-6348 or cdcinfo@cdc.gov. Hepatitis C Counseling and Testing, contact: 800-CDC-INFO (800-232-4636) Preface The purpose of this CDC Hepatitis C Counseling and Testing manual is to provide guidance for hepatitis C counseling and testing of individuals born during 1945 1965. The guide was used in draft

More information

Hepatitis C Infections in Oregon September 2014

Hepatitis C Infections in Oregon September 2014 Public Health Division Hepatitis C Infections in Oregon September 214 Chronic HCV in Oregon Since 25, when positive laboratory results for HCV infection became reportable in Oregon, 47,252 persons with

More information

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid

Epidemiology of Hepatitis C Infection. Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Epidemiology of Hepatitis C Infection Pablo Barreiro Service of Infectious Diseases Hospital Carlos III, Madrid Worldwide Prevalence of Hepatitis C 10% No data available WHO.

More information

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK

HIV and Hepatitis Co-infection. Martin Fisher Brighton and Sussex University Hospitals, UK HIV and Hepatitis Co-infection Martin Fisher Brighton and Sussex University Hospitals, UK Useful References British HIV Association 2010 http://www.bhiva.org/documents/guidelines/hepbc/2010/ hiv_781.pdf

More information

8. Hepatitis A, B, and C

8. Hepatitis A, B, and C This electron micrograph reveals the presence of hepatitis-b virus HBV "Dane particles", or virions. 8. Hepatitis A, B, and C Prevention: The most effective means to prevent transmission of infectious

More information

Case Finding for Hepatitis B and Hepatitis C

Case Finding for Hepatitis B and Hepatitis C Case Finding for Hepatitis B and Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Atlanta, Georgia, USA Division of Viral Hepatitis National Center

More information

The Epidemiology of Hepatitis A, B, and C

The Epidemiology of Hepatitis A, B, and C The Epidemiology of Hepatitis A, B, and C Jamie Berkes M.D. University of Illinois at Chicago jberkes@uic.edu Epidemiology: Definitions The study of the incidence and prevalence of diseases in large populations

More information

Placing Nation on the Path Toward the Elimination of Hepatitis C

Placing Nation on the Path Toward the Elimination of Hepatitis C Placing Nation on the Path Toward the Elimination of Hepatitis C John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for

More information

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain

HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain HCV in 2020: Any cases left? Rafael Esteban Hospital General Universitario Valle Hebron Barcelona. Spain Yes, still too many Measures to eradicate an Infectious Disease Prevention: Vaccination Screening

More information

Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics

Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Hepatitis C Virus Infection in Massachusetts: A tale of two epidemics Daniel Church, MPH Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals of presentation Provide an overview

More information

Viral Hepatitis C Testing Recommendations for Persons Born

Viral Hepatitis C Testing Recommendations for Persons Born Viral Hepatitis C Testing Recommendations for Persons Born 1945-1965 Local Health Departments and Hepatitis C: Webcast 1.3 Presented by: Claudia Vellozzi, M.D., M.P.H. Chief, Prevention Branch, Division

More information

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL

Hepatitis C. Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Hepatitis C Eliot Godofsky, MD University Hepatitis Center Bradenton, FL Recent Advances in Hepatitis C Appreciation that many patients are undiagnosed Improved screening to identify infected persons Assessment

More information

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016

William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 William Atkinson, MD, MPH Hepatitis B Vaccine Issues June 16, 2016 Advisory Committee on Immunization Practices (ACIP) The recommendations to be discussed are primarily those of the ACIP composed of 15

More information

HEPATITIS B The Importance of the Hepatitis B Vaccine

HEPATITIS B The Importance of the Hepatitis B Vaccine HEPATITIS B The Importance of the Hepatitis B Vaccine Since 1982, a hepatitis B vaccine has been available to prevent hepatitis B virus infection. Today, the vaccine is made using recombinant DNA technology

More information

What is hepatitis? Sources: WHO. Global Alert and Response. Hepatitis.

What is hepatitis? Sources: WHO. Global Alert and Response. Hepatitis. Viral hepatitis What is hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D, E Hepatitis A and E are typically caused

More information

After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH

After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH After the Cure: Long-Term Management of HCV Liver Disease Norah A. Terrault, MD, MPH Professor of Medicine Department of Gastroenterology Director, Viral Hepatitis Center University of California San Francisco

More information

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok

Management of hepatitis C: pre- and post-liver transplantation. Piyawat Komolmit Bangkok Management of hepatitis C: pre- and post-liver transplantation Piyawat Komolmit Bangkok Liver transplantation and CHC Cirrhosis secondary to HCV is the leading cause of liver transplantation in the US

More information

3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300.

3/25/2014. April 3, 2014. Dennison MM, et al. Ann Intern Med. 2014;160:293 300. April 3, 2014 3.6 million persons ever infected; 2.7 million chronic infections 1 Up to 75% unaware of status Transmitted through percutaneous exposure to infected blood Injection drug use (IDU) is the

More information

The Epidemiology of Hepatitis B and A Infections. Kenrad E. Nelson, MD Johns Hopkins University

The Epidemiology of Hepatitis B and A Infections. Kenrad E. Nelson, MD Johns Hopkins University This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike License. Your use of this material constitutes acceptance of that license and the conditions of use of materials on this

More information

Hepatitis A, B, C. This material is intended for insurance informational purposes only and is not personal medical advice for clients.

Hepatitis A, B, C. This material is intended for insurance informational purposes only and is not personal medical advice for clients. Hepatitis A, B, C Hepatitis is a general term referring to inflammation of the liver. The usual cause is viral, either Hepatitis A, B, or C. However, toxins and drugs may also induce a hepatitis. The onset

More information

Strategies to Improve the HCV Continuum of Care:

Strategies to Improve the HCV Continuum of Care: Strategies to Improve the HCV Continuum of Care: Best Practices in Testing, Linkage to Care & Treatment Ronald O. Valdiserri, M.D., M.P.H. Deputy Assistant Secretary for Health, Infectious Diseases June

More information

An Overview of NYS Hepatitis C Testing Law. Statewide Stakeholder Meetings

An Overview of NYS Hepatitis C Testing Law. Statewide Stakeholder Meetings An Overview of NYS Hepatitis C Testing Law Statewide Stakeholder Meetings Agenda Overview of Hepatitis C virus (HCV) CDC HCV screening recommendations Review of HCV screening and diagnostic tests CDC HCV

More information

Executive summary of recommendations

Executive summary of recommendations MOH CLINICAL PRACTICE GUIDELINES 2/2011 Chronic Hepatitis B Infection College of Family Physicians, Singapore Academy of Medicine, Singapore Singapore Medical Association Executive summary of recommendations

More information

Hepatitis C. Screening, Diagnosis and Linkage to Care

Hepatitis C. Screening, Diagnosis and Linkage to Care Hepatitis C Screening, Diagnosis and Linkage to Care Diagnosis If your hepatitis C antibody test is reactive, a second test will be needed to diagnose and determine if you are currently infected. Screening

More information

NOTIFIABLE. Infectious Disease Assessment for Migrants 2015 - 27 - RECOMMENDATIONS. Offer test (HBsAg and anti-hbc) to: Vaccinate:

NOTIFIABLE. Infectious Disease Assessment for Migrants 2015 - 27 - RECOMMENDATIONS. Offer test (HBsAg and anti-hbc) to: Vaccinate: 5.2 Hepatitis B NOTIFIABLE RECOMMENDATIONS Offer test (HBsAg and anti-hbc) to: = All new migrants originating from countries with a HBsAg prevalence of 2% = Household and sexual of identified acute or

More information

Hepatitis C Glossary of Terms

Hepatitis C Glossary of Terms Acute Hepatitis C A short-term illness that usually occurs within the first six months after someone is exposed to the hepatitis C virus (HCV). 1 Antibodies Proteins produced as part of the body s immune

More information

Hepatitis C Cascade of Care Principles for Primary Care Providers. Rodney K. Kusumi, MD

Hepatitis C Cascade of Care Principles for Primary Care Providers. Rodney K. Kusumi, MD Hepatitis C Cascade of Care Principles for Primary Care Providers Rodney K. Kusumi, MD How Common is Hepatitis C sexually Transmitted? Historical Landmarks- Infectious Diseases 1975 Lyme Disease 1976 Legionella

More information

HEPATITIS C DIAGNOSIS AND MANAGEMENT

HEPATITIS C DIAGNOSIS AND MANAGEMENT HEPATITIS C DIAGNOSIS AND MANAGEMENT Introduction The hepatitis C virus (HCV) is one of six viruses (A, B, C, D, E, G) that account for the majority of cases of viral hepatitis. It is responsible for about

More information

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS

12/2/2015 HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE OBJECTIVES VIRAL HEPATITIS HEPATITIS B AND HEPATITIS C BLOOD EXPOSURE DISEASE 101 ONLINE CONFERENCE SARAH WENINGER, MPH VIRAL HEPATITIS.STD.HIV PREVENTION COORDINATOR DECEMBER 3, 2015 OBJECTIVES Describe the populations that should

More information

Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice

Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Beginner's guide to Hepatitis C testing and immunisation against hepatitis A+B in general practice Dr Chris Ford GP & SMMGP Clinical Lead Kate Halliday Telford & Wrekin Shared Care Coordinator Aims Discuss:

More information

EPIDEMIOLOGY OF HEPATITIS B IN IRELAND

EPIDEMIOLOGY OF HEPATITIS B IN IRELAND EPIDEMIOLOGY OF HEPATITIS B IN IRELAND Table of Contents Acknowledgements 3 Summary 4 Introduction 5 Case Definitions 6 Materials and Methods 7 Results 8 Discussion 11 References 12 Epidemiology of Hepatitis

More information

Recommendations 8/14/2014. Hepatitis C Clinical Approach Primary Care. Purpose of Presentation. HCV Prevalence Year of Birth

Recommendations 8/14/2014. Hepatitis C Clinical Approach Primary Care. Purpose of Presentation. HCV Prevalence Year of Birth Hepatitis C Clinical Approach Primary Care Dr. Vicki L. MIt McIntyre, FNP Tucson Gastroenterology Specialists Tucson, Arizona University of Phoenix Lead Faculty, Department of Nursing Tucson, Arizona Purpose

More information

Guidelines for Viral Hepatitis CTR Services

Guidelines for Viral Hepatitis CTR Services Guidelines for Viral Hepatitis CTR Services During the 2007 North Dakota Legislative Assembly, legislation that called for the creation of a viral hepatitis program was introduced and approved. The North

More information

Cirrhosis and HCV. Jonathan Israel M.D.

Cirrhosis and HCV. Jonathan Israel M.D. Cirrhosis and HCV Jonathan Israel M.D. Outline Relationship of fibrosis and cirrhosisprevalence and epidemiology. Sequelae of cirrhosis Diagnosis of cirrhosis Effect of cirrhosis on efficacy of treatment

More information

Global Under Diagnosis of Viral Hepatitis

Global Under Diagnosis of Viral Hepatitis Global Under Diagnosis of Viral Hepatitis Mel Krajden MD, FRCPC Medical Head, Hepatitis Clinical Prevention Services Associate Medical Director, Public Health Microbiology & Reference Laboratory BC Centre

More information

New IDSA/AASLD Guidelines for Hepatitis C

New IDSA/AASLD Guidelines for Hepatitis C NORTHWEST AIDS EDUCATION AND TRAINING CENTER New IDSA/AASLD Guidelines for Hepatitis C John Scott, MD, MSc Associate Professor, UW SoM Asst Director, Liver Clinic, Harborview Medical Center Presentation

More information

HBV & HCV induced. Liver Cirrhosis Iradj Maleki MD Gut & Liver Research Center Mazandaran University of Medical Sciences

HBV & HCV induced. Liver Cirrhosis Iradj Maleki MD Gut & Liver Research Center Mazandaran University of Medical Sciences HBV & HCV induced Liver Cirrhosis Iradj Maleki MD Gut & Liver Research Center Mazandaran University of Medical Sciences Definition of Cirrhosis Final pathway for a wide variety of chronic liver diseases

More information

EMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN

EMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN EMERGING CLINICAL ISSUE: HEPATITIS C INFECTION IN HIV-INFECTED MEN WHO HAVE SEX WITH MEN JUNE 2014 INTRODUCTION Approximately 3.2 million individuals in the United States are infected with chronic hepatitis

More information

Are Booster Doses of Hepatitis B Vaccine Necessary?

Are Booster Doses of Hepatitis B Vaccine Necessary? Are Booster Doses of Hepatitis B Vaccine Necessary? Current CDC Recommendations And Gaps in Knowledge Division of Viral Hepatitis Centers for Disease Control and Prevention, USA Current United States Recommendations

More information

Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D.

Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China. Title. Charles Wang, M.D. Epidemiology of HCV and HIV/HCV Infection in Guangzhou, China Title Charles Wang, M.D. Background Hepatitis C infects 170 million worldwide & 3 million Chinese HIV infects 33.3 million worldwide & 740,000

More information

2015 Outpatient Chronic Hepatitis B Management

2015 Outpatient Chronic Hepatitis B Management 2015 Outpatient Chronic Hepatitis B Management Hepatitis B Hepatitis B Info 70% of acute infections are subclinical More severe symptoms when in addition to other liver disease Fulminant Hepatitis

More information

HCC: Risk factors, surveillance and the importance of a multidisciplinary team

HCC: Risk factors, surveillance and the importance of a multidisciplinary team HCC: Risk factors, surveillance and the importance of a multidisciplinary team Anjana Pillai MD Assistant Professor of Medicine Director, Emory University Hospital Liver Tumor Clinic Division of Digestive

More information

Commonly Asked Questions About Chronic Hepatitis C

Commonly Asked Questions About Chronic Hepatitis C Commonly Asked Questions About Chronic Hepatitis C From the American College of Gastroenterology 1. How common is the hepatitis C virus? The hepatitis C virus is the most common cause of chronic viral

More information

AND CURE, PART 1. EPIDEMIOLOGY, TRANSMISSION/PREVENTION, NATURAL HISTORY Tracy Swan Hepatitis/HIV Project Director Treatment Action Group DISCLOSURE

AND CURE, PART 1. EPIDEMIOLOGY, TRANSMISSION/PREVENTION, NATURAL HISTORY Tracy Swan Hepatitis/HIV Project Director Treatment Action Group DISCLOSURE HEPATITIS C VIRUS: TEST, TREAT AND CURE, PART 1 EPIDEMIOLOGY, TRANSMISSION/PREVENTION, NATURAL HISTORY Tracy Swan Hepatitis/HIV Project Director Treatment Action Group DISCLOSURE Ms. Swan has no disclosures

More information

Diagnosis of Acute HCV Infection

Diagnosis of Acute HCV Infection Hepatitis C Online PDF created August 23, 2016, 2:28 pm Diagnosis of Acute HCV Infection Module 1: Lesson 5: Contents: Screening and Diagnosis of Hepatitis C Infection Diagnosis of Acute HCV Infection

More information

Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C

Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C Epidemiology, Risk Factors, and Natural History of Chronic Hepatitis C Nalini K. Sharma, MD and Averell H. Sherker, MD FRCP (C) CONTENTS EPIDEMIOLOGY RISK FACTORS NATURAL HISTORY OF HCV CONCLUSIONS REFERENCES

More information

Viral Hepatitis. 2009 APHL survey report

Viral Hepatitis. 2009 APHL survey report Issues in Brief: viral hepatitis testing Association of Public Health Laboratories May Viral Hepatitis Testing 9 APHL survey report In order to characterize the role that the nation s public health laboratories

More information

Combating Hepatitis B & Hepatitis C in Rwanda

Combating Hepatitis B & Hepatitis C in Rwanda Combating Hepatitis B & Hepatitis C in Rwanda BY MINNIE KARANJA Hepatitis is not a commonplace disease. However, there have been rising cases of Hepatitis B and Hepatitis C infections and related deaths

More information

Primary causes of chronic liver disease

Primary causes of chronic liver disease Hepatitis Primary causes of chronic liver disease Hepatitis (Liver-Attacking) Viruses Hepatitis A fecal/oral, contaminated food, vaccine available Hepatitis B blood, semen, vertical (mother-child), vaccine

More information

HEPATITIS C. The Facts. Get Tested. Get Cured! Health

HEPATITIS C. The Facts. Get Tested. Get Cured! Health HEPATITIS C The Facts Get Tested. Get Cured! Health EVEN IF YOU FEEL HEALTHY, HEPATITIS C MAY BE DAMAGING YOUR LIVER. Your liver keeps you healthy in many ways, such as by removing toxins from your blood

More information

Disclosure of Conflicts of Interest Learner Assurance Statement:

Disclosure of Conflicts of Interest Learner Assurance Statement: Raj Reddy, MD Ruimy Family President's Distinguished Professor of Medicine Professor of Medicine in Surgery Director of Hepatology Director, Viral Hepatitis Center Medical Director, Liver Transplantation

More information

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS

Prospects for Vaccines against Hepatitis C Viruses. T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS Prospects for Vaccines against Hepatitis C Viruses T. Jake Liang. M.D. Liver Diseases Branch NIDDK, NIH, HHS HCV Vaccine Prevention strategies Protective immunity Barriers and solutions Vaccine candidates

More information

1.How did I get Hepatitis C?

1.How did I get Hepatitis C? 1.How did I get Hepatitis C? Sharing needles and syringes ( iv drug use ) or using contaminated straws to snort cocaine Reused needles or medications in a health care setting- (LV endoscopy outbreak, glucometers

More information

DISCLOSURE HEPATITIS C VIRUS: TEST, TREAT ASSESSMENT AND TREATMENT AND CURE PART 2: DIAGNOSTICS,

DISCLOSURE HEPATITIS C VIRUS: TEST, TREAT ASSESSMENT AND TREATMENT AND CURE PART 2: DIAGNOSTICS, HEPATITIS C VIRUS: TEST, TREAT AND CURE PART 2: DIAGNOSTICS, ASSESSMENT AND TREATMENT Tracy Swan Hepatitis/HIV Project Director Treatment Action Group DISCLOSURE Ms. Swan has no disclosures 1 LEARNING

More information

Hepatitis C and pregnancy

Hepatitis C and pregnancy Hepatitis C and pregnancy Assess HCV status at first visit Unknown HCV status If HCV + status based only on EIA +, order confirmatory RT-PCR Known HCV + status (RIBA or RT-PCR +) Hepatitis C Risk Factors

More information

Hepatitis C Testing Toolkit for Primary Care Providers. Resources to Support Hepatitis C Testing in Georgia

Hepatitis C Testing Toolkit for Primary Care Providers. Resources to Support Hepatitis C Testing in Georgia Hepatitis C Testing Toolkit for Primary Care Providers Resources to Support Hepatitis C Testing in Georgia 2015 Hepatitis C Testing Toolkit for Primary Care Providers How to use this file: This file includes

More information

Viral Hepatitis A, B, and C

Viral Hepatitis A, B, and C Viral Hepatitis A, B, and C What is Hepatitis? Hepatitis means inflammation of the liver Elizabeth A. Bancroft, MD, SM Acute Communicable Disease Control County of Los Angeles Department of Public Health

More information

National Health Burden of CLD in Italy

National Health Burden of CLD in Italy National Health Burden of CLD in Italy 11,000 deaths due to liver cirrhosis or HCC in 2006 Direct costs for the National Health System for treating CLD patients: 420 M / year for hospital care 164 M /

More information

GUIDELINES FOR THE MANAGEMENT OF HEPATITIS C

GUIDELINES FOR THE MANAGEMENT OF HEPATITIS C GUIDELINES FOR THE MANAGEMENT OF HEPATITIS C HEPATITIS, VIRAL A brief overview of hepatic viruses other than C - - The hepatitis A virus (HAV) infection is usually acquired by the fecal-oral route, produces

More information

Viral Hepatitis Case Report

Viral Hepatitis Case Report Page 1 of 9 Viral Hepatitis Case Report Perinatal Hepatitis B Virus Infection Michigan Department of Community Health Communicable Disease Division Investigation Information Investigation ID Onset Date

More information

GUIDELINES FOR VIRAL HEPATITIS SURVEILLANCE AND CASE MANAGEMENT

GUIDELINES FOR VIRAL HEPATITIS SURVEILLANCE AND CASE MANAGEMENT GUIDELINES FOR VIRAL HEPATITIS SURVEILLANCE AND CASE MANAGEMENT January 2005 Guidelines for Viral Hepatitis Surveillance and Case Management Ordering information To order a copy of this manual, write to:

More information

HCV Epidemiology in the United States

HCV Epidemiology in the United States HCV Epidemiology in the United States Scott Holmberg, MD, MPH Chief, Epidemiology and Surveillance Branch, DVH, CDC sdh1@cdc.gov A Tale of Two Epidemics Chronic HCV: Rapidly increasing mortality and morbidity

More information

THE A, B, C S OF HEPATITIS. Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas 75075 (972) 867-0019

THE A, B, C S OF HEPATITIS. Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas 75075 (972) 867-0019 THE A, B, C S OF HEPATITIS Matt Eidem, M.D. Digestive Health Associates of Texas 1600 Coit Road Suite #301 Plano, Texas 75075 (972) 867-0019 WHAT IS HEPATITIS? Hepatitis means inflammation of the liver

More information

Treatment of Acute Hepatitis C

Treatment of Acute Hepatitis C Management of Patients with Viral Hepatitis, Paris, 2004 Treatment of Acute Hepatitis C Michael P. Manns, Andrej Potthoff, Elmar Jaeckel, Heiner Wedemeyer Hepatitis C Virus (HCV) infection is a common

More information

BURDEN OF LIVER DISEASE IN BRAZIL

BURDEN OF LIVER DISEASE IN BRAZIL BURDEN OF LIVER DISEASE IN BRAZIL Burden of Liver Disease in Europe Blachier et al. J Hepatol 58:593, 2013 Review of 260 epidemiologic studies of the 5 previous years Cirrhosis is responsible for 170.000

More information

Screening for Bloodborne. Unit. A Sarabia MD

Screening for Bloodborne. Unit. A Sarabia MD Screening for Bloodborne Pathogens in the Hemodialysis Unit A Sarabia MD Objectives To review the rationale for bloodborne pathogen screening To review relevant characteristics of bloodborne pathogen infections:

More information

ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES

ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES ALASKA NATIVE MEDICAL CENTER SEXUALLY TRANSMITTED DISEASE SCREENING AND TREATMENT GUIDELINES A. Screening Page Chlamydia and Gonorrhea 1 HIV 1 Syphilis 1 Genital Herpes 2 Hepatitis A 2 Hepatitis B 2 Hepatitis

More information

Value of New Direct Acting Anti-Viral (DAA) to Treat Hepatitis C Infection

Value of New Direct Acting Anti-Viral (DAA) to Treat Hepatitis C Infection Value of New Direct Acting Anti-Viral (DAA) to Treat Hepatitis C Infection ISPOR 7th Asia-Pacific Conference, Singapore Saturday, 3 September 2016: 5:15PM-6:15PM Moderator: Yen-Huei (Tony) Tarn, PhD, Associate

More information

Liver Cancer and Clinical Trials

Liver Cancer and Clinical Trials Liver Cancer and Clinical Trials Abby Siegel MD, MS Medical Director, Hepatobiliary Oncology Columbia University Medical Center Tony Wang MD Assistant Professor, Radiation Oncology, Columbia University

More information

Hepatitis C: Reducing Incidence

Hepatitis C: Reducing Incidence Hepatitis C: Reducing Incidence Brian R. Edlin, MD, FACP, FIDSA Senior Principal Investigator National Development and Research Institutes Associate Professor of Medicine Weill Cornell Medical College

More information

National HCV Epidemiologic Trends

National HCV Epidemiologic Trends National HCV Epidemiologic Trends Scott Holmberg, MD, MPH Chief, Epidemiology and Surveillance Branch, DVH, CDC sdh1@cdc.gov Why surveillance is a critical and manifold function of CDC To detect outbreaks

More information

HEPATITIS C BREAKTHROUGHS: NEW CURES, BEST PRACTICE & HEALTH EQUITY

HEPATITIS C BREAKTHROUGHS: NEW CURES, BEST PRACTICE & HEALTH EQUITY HEPATITIS C BREAKTHROUGHS: NEW CURES, BEST PRACTICE & HEALTH EQUITY Jessica Leston jleston@npaihb.org or jessica.leston@ihs.gov Program Manager, HIV/STI/HCV Northwest Portland Area Indian Health Board

More information

HBV DNA < monitoring interferon Rx

HBV DNA < monitoring interferon Rx Hepatitis B Virus Suspected acute hepatitis >>Order: Acute Unknown hepatitis screen Suspected chronic hepatitis >>Order: Chronic unknown hepatitis screen Acute HBV or Delayed Anti HBs response after acute

More information

Briefing Note: Hepatitis B & Hepatitis C. Summary:

Briefing Note: Hepatitis B & Hepatitis C. Summary: Briefing Note: Hepatitis B & Hepatitis C Summary: In Canada, hepatitis B and hepatitis C infections remain serious public health concerns due to high prevalence rates, high health care expenditures and

More information

Epidemiology of HIV Infection United States 2013

Epidemiology of HIV Infection United States 2013 Epidemiology of HIV Infection United States 2013 John T. Brooks, M.D. Epidemiology Branch Division of HIV/AIDS Prevention, CDC The findings and conclusions in this presentation are those of the author

More information

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII)

When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) XI. OCCUPATIONAL EXPOSURES TO HEPATITIS B AND C RECOMMENDATION: When an occupational exposure occurs, the source patient should be evaluated for both hepatitis B and hepatitis C. (AII) The risk of transmission

More information

João Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil

João Silva de Mendonça, MD, PhD Infectious Diseases Service Hospital do Servidor Público Estadual São Paulo - Brazil Brazilian Ministry of Health, Brazilian Society of Hepatology PAHO, Viral Hepatitis Prevention Board PART III SESSION 9 Prevention and control of Viral Hepatitis in Brazil HEPATITIS IN SPECIAL RISK GROUPS/

More information

HBC-1. If the case had jaundice, tick the Yes box. If not, tick the No box. If not known or unavailable then tick the Unknown box.

HBC-1. If the case had jaundice, tick the Yes box. If not, tick the No box. If not known or unavailable then tick the Unknown box. HBC-1 HEPATITIS B, C, NOS Disease Name Disease Indicate whether the case is hepatitis B, C or NOS (Not Otherwise Specified). Use NOS for cases of hepatitis D or E or if the type of hepatitis has not been

More information

Using Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services

Using Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services Using Substance Abuse Prevention and Treatment (SAPT) Block Grant HIV Set- Aside Funds for Integrated Services ADP Training Conference, Sacramento, August 21, 2012 Rachel McLean, MPH, CA Dept. of Public

More information

TESTING AND MANAGEMENT. Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL

TESTING AND MANAGEMENT. Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL TESTING AND MANAGEMENT Dr Nicole Allard GP Cohealth, Joslin Clinic, West Footscray PhD student, Epidemiology Unit VIDRL Disclosure and acknowledgments No conflicts of interest Board Member of Hepatitis

More information

UPDATE ON NEW HEPATITIS C MEDICINES

UPDATE ON NEW HEPATITIS C MEDICINES UPDATE ON NEW HEPATITIS C MEDICINES Diana Sylvestre, MD 2014 AASLD/IDSA Guidelines: Gt 1 Treatment naïve Interferon eligible: sofosuvir + ribavirin + PEG-IFN x 12 weeks Interferon ineligible: sofosbuvir

More information

Infection reports. Acute hepatitis B (England): annual report for Immunisation

Infection reports. Acute hepatitis B (England): annual report for Immunisation Infection reports Volume 8 Number 33 Published on: 22 August 2014 Immunisation Acute hepatitis B (England): annual report for 2013 Introduction Hepatitis B is a blood borne infection of the liver caused

More information

Management of Hepatitis C: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians

Management of Hepatitis C: Review of the Performance Measures by the Performance Measurement Committee of the American College of Physicians Performance ment Management of Hepatitis C: Review of the Performance s by the Performance ment Committee of the American College of Physicians Writing Committee Amir Qaseem, MD, Andrew Dunn, MD, Stephen

More information

Indicate whether the case had jaundice. If not known or unavailable then select the Unknown option.

Indicate whether the case had jaundice. If not known or unavailable then select the Unknown option. HBC-1 HEPATITIS B, C, NOS Disease name Disease Indicate whether the case is hepatitis B, C or NOS (Not Otherwise Specified). Select hepatitis NOS for cases of hepatitis D, hepatitis E or if the type of

More information

Increase of sexually transmitted hepatitis C virus in HIV+ men who have sex with men in Barcelona, Spain. A problem linked to HIV infection?

Increase of sexually transmitted hepatitis C virus in HIV+ men who have sex with men in Barcelona, Spain. A problem linked to HIV infection? Increase of sexually transmitted hepatitis C virus in HIV+ men who have sex with men in Barcelona, Spain. A problem linked to HIV infection? S. Manzanares-Laya 1, P. García de Olalla 1,2, C. Garriga 1,3,

More information

Information about hepatitis C for patients and carers

Information about hepatitis C for patients and carers Information about hepatitis C for patients and carers What is hepatitis C? Hepatitis C is an illness caused by a virus which can be passed through blood from one person to another. It mainly affects the

More information

Evaluation and Prognosis of Patients with Cirrhosis

Evaluation and Prognosis of Patients with Cirrhosis Evaluation and Prognosis of Patients with Cirrhosis Marion G. Peters, MD John V. Carbone, MD, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco Recorded

More information

HCC in HIV who and how to screen. Raffaele Bruno,MD

HCC in HIV who and how to screen. Raffaele Bruno,MD HCC in HIV who and how to screen Raffaele Bruno,MD Dipartimento di Scienze Cliniche Chirurgiche Diagnostiche e Pediatriche Università degli Studi di Pavia U.O. Malattie Infettive e Tropicali Fondazione

More information

Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease

Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease Consequences of Hepatitis C Virus (HCV): Costs of a Baby Boomer Epidemic of Liver Disease MAY 2009 Commissioned by Vertex Pharmaceuticals Incorporated Bruce Pyenson, FSA, MAAA Principal & Consulting Actuary

More information

When to Consider Liver Transplantation for Patients with Hepatitis C

When to Consider Liver Transplantation for Patients with Hepatitis C Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/advances-in-transplantation/when-to-consider-liver-transplantation-forpatients-with-hepatitis-c/6366/

More information

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

BACKGROUND MEDIA INFORMATION Fast facts about liver disease BACKGROUND MEDIA INFORMATION Fast facts about liver disease Liver, or hepatic, disease comprises a wide range of complex conditions that affect the liver. Liver diseases are extremely costly in terms of

More information

Co-infected health-care workers

Co-infected health-care workers Co-infected health-care workers Y.Yazdanpanah Service Universitaire des Maladies Infectieuses et du Voyageur C.H. Tourcoing, Faculté de Médecine de Lille CNRS U362, Lille, France Co-infected health-care

More information

Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine

Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease. From : New England Journal of Medicine Lamivudine for Patients with hronic Hepatitis B and Advanced Liver Disease From : New England Journal of Medicine Volume 351:1521-1531, Number 15, Oct 7, 2004 馬 偕 紀 念 醫 院 一 般 內 科, 肝 膽 腸 胃 科 新 竹 分 院 陳 重

More information

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto

PREVENTION OF HCC BY HEPATITIS C TREATMENT. Morris Sherman University of Toronto PREVENTION OF HCC BY HEPATITIS C TREATMENT Morris Sherman University of Toronto Pathogenesis of HCC in chronic hepatitis C Injury cirrhosis HCC Injury cirrhosis HCC Time The Ideal Study Prospective randomized

More information